Abstract:Objective: Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is of concern because of its propensity for rapid deterioration and high mortality. Its aetiology and mechanism are still unclear. The aims of this study were to clarify the pathophysiology differences between AE-IPF and stable IPF (S-IPF) by comparing the serum levels of various cytokines and chemokines in the two groups and to identify those involvement in the occurrence of acute exacerbation and associated with mortality. Methods: The study included 28 patients with AE-IPF, 32 patients with S-IPF, and 18 healthy control subjects. We measured the serum cytokine and chemokine levels in all cases by multiplex assay. Serum levels of cytokines and chemokines were compared between AE-IPF and S-IPF subjects. Logistic regression analysis was applied to identify the ability of these variables to predict acute exacerbation. Kaplan-Meier curves were used to analyse survival and Cox proportional hazard regression was used to identify predictors of survival. Results: Levels of several cytokines and chemokines were significantly higher in both patient groups with IPF (with the exception of interleukin-2 [IL-2], chemokine cc-motif ligand 3, and RANTES [regulation upon activation normal T-cell express sequence]) than in healthy controls. Serum IL-1 beta (p = 0.008) and interferon (IFN)-gamma (p = 0.007) levels tended to be higher in patients with AE-IPF than in those with S-IPF. The concentration of chemokine cc-motif ligand (CCL) 2 was significantly higher in bronchoalveolar lavage fluid than in serum (p = 0.001). Higher C-reactive protein, lactate dehydrogenase, percent forced vital capacity, percent diffusing capacity of the lung for carbon monoxide, and IFN-gamma values in the patients with IPF were correlated with acute exacerbation status, with respective odds ratios of 1.241 (p = 0.011), 1.050 (p = 0.004), 1.043 (p = 0.001), 0.927 (p = 0.014), and 0.929 (p = 0.020). Acute exacerbation status was associated with an increased risk of mortality (hazard ratio 0.107, 95% confidence interval 0.036-0.314; p < 0.001). Univariate Cox regression demonstrated an association of IFN-gamma, CCL2, C-X-C motif chemokine 10 (CXCL10) and sCD163 levels with an increased mortality risk (p = 0.015, p = 0.002, p = 0.001, and p = 0.030, respectively). Conclusions: Our data demonstrate that serum levels of some pro-inflammatory cytokines and macrophage chemokines are upregulated during acute exacerbations of IPF and that these exacerbations are associated with the serum IFN-gamma level. Chemokines and protein such as sCD163, CCL2, and CXCL10 are associated with activation of macrophages and may have a serious impact on overall survival in patients with IPF.

Pre-Treatment Ferritin Level and Alveolar-Arterial Oxygen Gradient Can Predict Mortality Rate Due to Acute/Subacute Interstitial Pneumonia in Dermatomyositis Treated by Cyclosporine A/Glucocorticosteroid Combination Therapy: A Case Control Study

Plasma IL-6/IL-10 Ratio and IL-8, LDH, and HBDH Level Predict the Severity and the Risk of Death in AIDS Patients with Pneumocystis Pneumonia.

One-year Survival Follow-Up and Risk Factors Analysis of Clinically Amyopathic Dermatomyositis Complicated by Acute/subacute Interstitial Pneumonia

Amyopathic dermatomyositis complicated by acute/subacute interstitial pneumonia:a 13-year retrospective analysis

Acute/subacute interstitial lung disease in clinically amyopathic dermatomyositis(CADM) patients:a retrospective study of 101 cases

HRCT Score and Serum Ferritin Level Are Factors Associated to the 1-Year Mortality of Acute Interstitial Lung Disease in Clinically Amyopathic Dermatomyositis Patients.

Clinical study of acute/subacute interstitial pneumonia in patients with dermatomyositis

Prognostic Factors for Mortality in Patients With Autoimmune Diseases Complicated by Pneumocystis Pneumonia

Correlation of increased serum leucine-rich α2-glycoprotein levels with disease prognosis, progression, and activity of interstitial pneumonia in patients with dermatomyositis: A retrospective study

Multivariate logistic regression analysis of poor prognosis of dermatomyositis and clinical value of ferritin/Kl-6 in predicting prognosis

Treatment of Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis: A Retrospective Study of 87 Patients

The relationship between immunosuppressive therapy and clinical isolates for patients diagnosed with dermatomyositis-related interstitial lung diseases

Surfactant Protein D is Associated with 3-Month Mortality of Anti-Mda5 Antibody-Interstitial Lung Disease

Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study

Clinical course and prognostic factors of Pneumocystis pneumonia with respiratory failure in non-HIV patients

Pneumocystis jirovecii pneumonia increases the 3-months mortality of anti-MDA5-antibody-positive dermatomyositis patients

Prognostic Value of IFN-γ, Scd163, CCL2 and CXCL10 Involved in Acute Exacerbation of Idiopathic Pulmonary Fibrosis

The Predictive Factors and Unfavourable Prognostic Factors of Interstitial Lung Disease in Patients with Polymyositis/dermatomyositis

Idiopathic fibrotic lung disease at a university hospital setting: management and prognostic factors

Risk Factors of Interstitial Lung Diseases in Clinically Amyopathic Dermatomyositis

Cytokeratin 19 fragment is associated with severity and poor prognosis of interstitial lung disease in anti-MDA5 antibody-positive dermatomyositis